Thanks tig, gs5816 looks like my only option W/solv-most likley W/riba. Cant wait to go down the riba road again. (not really) RC
Tig said
Dec 14, 2014
Hey RC,
No name that I've seen discussed yet. As long as it remains in trials, the name is kept secret for marketing and patent rights.
Tig
robertsamx said
Dec 14, 2014
I wish I could get into this trial NCT02201953 but its randomized and one arm is W/O gs5816 Does GS5816 have a drug name yet? I cant find any info on it?? Thanks all RC
-- Edited by robertsamx on Sunday 14th of December 2014 05:56:17 AM
-- Edited by robertsamx on Sunday 14th of December 2014 06:03:56 AM
mallani said
Dec 13, 2014
Hi Tig,
Good article and it gives hope to the Rx-failed Geno 3 cirrhotics.
I guess Gilead will co-formulate Sovaldi and GS-5816 into a single pill, so that will be another interesting pricing decision.
At last we're starting to hear about RAV's at the NS-5A site. More to come I hope. Cheers.
Tig said
Dec 13, 2014
Interesting article on the newest pan-genotypic protocol in development. Is this the answer? For those interested, there is a link at the bottom (of artiicle) to the Clinical trials website with info on the current "Astral 3" study underway. We have discussed this before but the new articles provide insight and hope!
Thanks tig, gs5816 looks like my only option W/solv-most likley W/riba. Cant wait to go down the riba road again. (not really) RC
Hey RC,
No name that I've seen discussed yet. As long as it remains in trials, the name is kept secret for marketing and patent rights.
Tig
I wish I could get into this trial NCT02201953 but its randomized and one arm is W/O gs5816 Does GS5816 have a drug name yet? I cant find any info on it?? Thanks all RC
-- Edited by robertsamx on Sunday 14th of December 2014 05:56:17 AM
-- Edited by robertsamx on Sunday 14th of December 2014 06:03:56 AM
Hi Tig,
Good article and it gives hope to the Rx-failed Geno 3 cirrhotics.
I guess Gilead will co-formulate Sovaldi and GS-5816 into a single pill, so that will be another interesting pricing decision.
At last we're starting to hear about RAV's at the NS-5A site. More to come I hope. Cheers.
Interesting article on the newest pan-genotypic protocol in development. Is this the answer? For those interested, there is a link at the bottom (of artiicle) to the Clinical trials website with info on the current "Astral 3" study underway. We have discussed this before but the new articles provide insight and hope!
http://mobile.aidsmap.com/Sofosbuvir-GS-5816-for-12-weeks-shows-high-HCV-cure-rates-but-8-weeks-is-less-effective-for-some-patients/page/2923542
Tig